These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26678656)

  • 1. Mortality in Individuals Treated With Glucose-Lowering Agents: A Large, Controlled Cohort Study.
    Claesen M; Gillard P; De Smet F; Callens M; De Moor B; Mathieu C
    J Clin Endocrinol Metab; 2016 Feb; 101(2):461-9. PubMed ID: 26678656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
    Bowker SL; Majumdar SR; Veugelers P; Johnson JA
    Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.
    Johnson JA; Majumdar SR; Simpson SH; Toth EL
    Diabetes Care; 2002 Dec; 25(12):2244-8. PubMed ID: 12453968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias.
    Bowker SL; Lin M; Eurich DT; Johnson JA
    Can J Diabetes; 2017 Apr; 41(2):204-210. PubMed ID: 27908558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
    Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
    Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary heart disease outcomes in patients receiving antidiabetic agents.
    McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
    Hippisley-Cox J; Coupland C
    BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.
    Bannister CA; Holden SE; Jenkins-Jones S; Morgan CL; Halcox JP; Schernthaner G; Mukherjee J; Currie CJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1165-73. PubMed ID: 25041462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.
    Vaccaro O; Masulli M; Bonora E; Del Prato S; Giorda CB; Maggioni AP; Mocarelli P; Nicolucci A; Rivellese AA; Squatrito S; Riccardi G;
    Nutr Metab Cardiovasc Dis; 2012 Nov; 22(11):997-1006. PubMed ID: 23063367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes.
    Currie CJ; Poole CD; Evans M; Peters JR; Morgan CL
    J Clin Endocrinol Metab; 2013 Feb; 98(2):668-77. PubMed ID: 23372169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Impact of Hypoglycemic Agents on Severity and Extent of Myocardial Ischemia in Patients With Type 2 Diabetes Mellitus Undergoing Myocardial Perfusion Scintigraphy.
    Biondi-Zoccai G; Pinto A; Versaci F; Procaccini E; Neri G; Sesti G; Uccioli L; Vetere M; Peruzzi M; Nudi F
    J Cardiovasc Pharmacol; 2016 Aug; 68(2):162-70. PubMed ID: 27074768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer and bone fractures in observational follow-up of the RECORD study.
    Jones NP; Curtis PS; Home PD
    Acta Diabetol; 2015 Jun; 52(3):539-46. PubMed ID: 25524432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke.
    Floyd JS; Wiggins KL; Sitlani CM; Flory JH; Dublin S; Smith NL; Heckbert SR; Psaty BM
    Diabetes Obes Metab; 2015 Dec; 17(12):1194-7. PubMed ID: 26179389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neither diabetes nor glucose-lowering drugs are associated with mortality after noncardiac surgery in patients with coronary artery disease or heart failure.
    Hanninen M; McAlister FA; Bakal JA; van Diepen S; Ezekowitz JA
    Can J Cardiol; 2013 Apr; 29(4):423-8. PubMed ID: 22985785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up.
    Fisman EZ; Tenenbaum A; Benderly M; Goldbourt U; Behar S; Motro M
    Cardiology; 1999; 91(3):195-202. PubMed ID: 10516414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality Associated with Metformin Versus Sulfonylurea Initiation: A Cohort Study of Veterans with Diabetes and Chronic Kidney Disease.
    Marcum ZA; Forsberg CW; Moore KP; de Boer IH; Smith NL; Boyko EJ; Floyd JS
    J Gen Intern Med; 2018 Feb; 33(2):155-165. PubMed ID: 29181788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study.
    Sillars B; Davis WA; Hirsch IB; Davis TM
    Diabetes Obes Metab; 2010 Sep; 12(9):757-65. PubMed ID: 20649627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
    Rascati K; Richards K; Lopez D; Cheng LI; Wilson J
    Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis.
    Kowall B; Rathmann W; Kostev K
    Diabetes Care; 2015 Jan; 38(1):59-65. PubMed ID: 25336750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.